Passage Bio, Inc.
PASG
$0.3117
-$0.0145-4.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.03% | -11.40% | -19.27% | -15.90% | -7.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.64% | -31.68% | -33.28% | -26.58% | -16.70% |
| Operating Income | 22.64% | 31.68% | 33.28% | 26.58% | 16.70% |
| Income Before Tax | 24.07% | 28.66% | 32.97% | 51.33% | 38.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.07% | 28.66% | 32.97% | 51.33% | 38.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.07% | 28.66% | 32.97% | 51.33% | 38.10% |
| EBIT | 22.64% | 31.68% | 33.28% | 26.58% | 16.70% |
| EBITDA | 23.18% | 32.14% | 33.87% | 26.95% | 16.79% |
| EPS Basic | 32.65% | 36.72% | 40.59% | 52.79% | 38.43% |
| Normalized Basic EPS | 32.60% | 40.60% | 42.21% | 29.63% | 20.53% |
| EPS Diluted | 32.65% | 36.72% | 40.59% | 52.38% | 38.43% |
| Normalized Diluted EPS | 32.60% | 40.60% | 42.21% | 29.63% | 20.53% |
| Average Basic Shares Outstanding | 12.72% | 12.73% | 12.80% | 3.07% | 0.55% |
| Average Diluted Shares Outstanding | 12.72% | 12.73% | 12.80% | 3.07% | 0.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |